title: Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast.
abstract: OBJECTIVE
  To investigate KAI1 and survivin expression in infiltrating ductal carcinomas, and to evaluate the relationship between clinicopathological factors and KAI1 and survivin expression levels in breast cancers.
  
  
  RESULTS
  KAI and survivin expression levels were measured in 62 patients, using immunohistochemical staining. Western blot analysis was performed on eight frozen cases. DNA ploidy was determined by flow cytometry. The results of the KAI1 expression analyses were as follows: in 14 cases (22.6%) levels were preserved (++), in 30 cases (48.4%) levels were reduced (+), in 18 cases (29.0%) no KAI1 expression was detected, so these were designated 'lost' (-). Results of assessments of survivin expression were as follows: six cases (9.7%) were strong positive (++), 28 cases (45.15%) were positive (+), and 28 cases (45.15%) were negative. Survivin (p=0.0009) and KAI1 (p=0.0091) expression levels were directly correlated with survival rate. However, no significant difference was determined to exist between survivin and KAI1 expression levels and the clinicopathological factors. DNA ploidy did not correlate with survivin and KAI1 expression levels and survival rate. Four different groups, according to their survivin and KAI1 expression levels, correlated with the clinical stage and survival rate.
  
  
  CONCLUSIONS
  KAI1 and survivin expression levels might be prognostic factors in breast cancers.
authors: Department of General Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine [corrected] Seoul, Korea.
authors: B H
authors: BH
authors: Son
authors: J S
authors: JS
authors: Choi
authors: J H
authors: JH
authors: Lee
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D004273:DNA, Neoplasm / Q000032:analysis; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins; D009367:Neoplasm Staging; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D011003:Ploidies; D011379:Prognosis; D015996:Survival Rate; D000077022:Survivin
chemical_list: C076266:ANOS1 protein, human; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D016326:Extracellular Matrix Proteins; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D000077022:Survivin